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Objective: To evaluate the prevalence of anti-HCV antibodies using subjects hospitalized in  surgical departments and 
medical wards, and out-patients; secondly, t o  assess the evidence for developing chronic hepatitis in subjects positive 
for anti-HCV when compared with those with hepatitis B virus (HBV). 
Methods: 21 888 serum samples from 18380 subjects were investigated for anti-HCV antibodies using second and third 
generation immunoenzymatic assays. Some of these subjects were hospitalized patients and some were out-patients. 
Results: The study showed a 12.8% overall anti-HCV prevalence rate with significant differences between out-patients 
(16.5%) or subjects hospitalised in medical wards (ISYO) and in-patients in  surgical departments (7.7%). The third group 
incfuded asymptomatic subjects over twenty years old whose sera were tested for anti-HCV antibodies as part of routine 
preoperation screening and not on clinical suspicion. Hence, this group, too, can be considered as representative of the 
general population, and the prevalence of anti-HCV antibodies observed among them as the prevalence of anti-HCV 
antibodies in the general population in a northern Italian area. The data, following a confirmatory test (RIBA) on positive 
samples, were analysed for their positivity t o  different antigens (the simultaneous presence of antibodies to the C-100, 
C-33 and C-22 antigens), as an index of developing chronic viral activity. This was observed in  63.4% of positive patients 
from surgical departments. 
Conclusions: There is a large proportion of the asymptomatic population which could be chronically infected. 
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INTRODUCTION 
Hepatitis C virus (HCV) has been recognized since 
1989 as a major cause of parenterally transmitted non- 
A non-B hepatitis [1,2]. Primary HCV infection is 
asymptomatic in 90-9596 of cases [3] and is only 
accidentally revealed by abnormal liver function tests 
and/or testing for antibomes to HCV [4]. 
Acute infections are usually benign; fulminant 
hepatitis is extremely rare. Despite a lower prevalence 
of anti-HCV antibodies compared with other viral 
causes of hepatitis, such as hepatitis B, infection with 
HCV is very likely to become chronic [5,6]. The 
clinical spectrum of such chronic HCV infection varies 
from an asymptomatic carrier status without liver 
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damage to clinically apparent and rapidly progressive 
hepatitis advancing to cirrhosis in a few years [7,8]. 
Nevertheless, progression to cirrhosis occurs over time 
(20-30 years) in about 30% of cases [9]. Surveys on 
the prevalence of antibodies to HCV, performed 
in different countries, have usually been focused on 
specific target populations, such as risk groups (trans- 
fused patients, intravenous drug users, patients with 
hemophilia or on dialysis), patients with chronic liver 
diseases or blood donors [10,11]. 
Anti-HCV prevalence has usually been shown to 
be relatively low among blood donors (about 1% in 
Europe and in North America, and 1-3% in the Middle 
East and Asia) [12], when compared with risk groups: 
60-80% among hemophiliacs [I31 or drug users, and 
15% among dialysis patients [14]. However, such groups 
are not representative of the general population [ 15,161. 
The aims of this study were: first, to evaluate the 
prevalence of anti-HCV antibodies using a wide sample 
of subjects hospitalized in surgical departments, as 
representative of the general population of a northern 
Italian area, of those in medical wards and of out- 
patients; second, to assess the evidence for developing 
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chronic hepatitis in subjects positive for anti-HCV 
compared with those with hepatitis B virus (HBV). 
MATERIALS AND METHODS 
Sera 
Between 1993 and 1996, 21888 serum samples were 
tested for anti-HCV antibodies taken from 18380 
subjects, 9856 females and 8524 males, among the 
population of Parma, northern Italy. Among these 
subjects, 13 128 were hospitalized patients and the 
others were outpatients. The analyzed subjects came 
from three groups, according to the departments they 
attended: the first group comprised 7326 patients aged 
over 20 from surgical departments, the second group 
comprised 5802 patients from medical wards, and the 
third group comprised 5252 outpatients. Those in the 
second and third groups were of all ages. 
Laboratory tests 
HCV test 
AU sera were screened for anti-HCV antibodies by an 
enzyme-linked immunosorbent assay (ELISA) (Ortho 
HCV ELISA Diagnostic Systems, a Johnson and Johnson 
company, Raritan, NJ), using a second-generation 
assay until March 1993 and subsequently with third- 
generation kits. Samples were considered reactive when 
their optical density values (OD) were equal to or 
higher than the OD value of the cut-off as indicated by 
the manufacturer (the cut-off value is the mean of three 
negative control OD values plus 0.600). 
Reactive sera were then tested with a recombinant 
immunoblot assay (second and third generations of 
Chiron RIBA HCV strip immunoblot assay). The 
RIBA test employs the same antigens as the ELISA test, 
but placed as individual bands on nitrocellulose strips. 
According to the manufacturer’s instructions, anti- 
HCV positivity was confirmed when two or more 
reactive bands were detected. 
HBV test 
Hepatitis B surface antigen (HBsAg), antibodies to 
HBV core antigen (anti-HBc) and anti-HBs were 
assayed by Abbott Auszyme monoclonal, Corzyme and 
Ausab respectively. Sera positive for Hl3sAg were 
retested with a confirmatory enzyme immunoassay 
(EIA). Anti-HBc IgM antibodes were assayed by a 
microparticle enzyme immunoassay (Abbott Corzyme- 
M). 
Statistical analysis 
The chi-squared test was used for examining data 
derived from HCV analyses in order to determine the 
significance of differences in the groups analyzed. A 
p value of less than 0.05 was considered to have 
statistical significance. 
RESULTS 
The overall prevalence of anti-HCV antibodies was 
assayed in sera from 18 380 subjects using EIA and the 
RIBA (Table 1). Antibodies reacting in the EIA were 
found in 2759 subjects; the RIBA test was performed 
on all these EIA positives and 2359 were confirmed, 
representing 12.8% of the entire population examined. 
The rates of anti-HCV positivity showed a statistically 
significant difference (p<O.Ol) between males (14.4%) 
and females (1 1.5%). 
Table 2 shows the data obtained from the 18380 
subjects according to their different hospital depart- 
ments. A statistically significant difference (p cO.01) 
was observed between the prevalence observed in the 
surgical departments (7.7%) and those in medical wards 
(16%) or in the outpatient group (16.5%). 
The positivity rates in the different departments 
were also analyzed according to sex (Table 2). No 
significant difference was observed in the medical 
wards, where positivity was 15.8% among males and 
16.2% among females. In contrast, a significant 
difference was observed both in the outpatient group, 
where positivity was 19.4% among males and 14% 
among females (p<O.Ol), and in the surgical depart- 
ments where positivity was 8.8% among males and 7% 
among females (p<0.01). 
Table 3 shows that 69.7% of the HCV RIBA- 
positive patients showed the simultaneous presence 
Table 1 Prevalence of anti-HCV antibodies in 18 380 subjects of the area of Parma 
Females Males Total 
No. % No. % No. % 
HCV Positive 1131 11.5 1228 14.4 2359 12.8 
HCV Indeterminate 22 1 2.2 179 2.1 400 2.2 
HCV Negative 8504 86.3 7117 83.5 15621 85 
Total 9856 100 8524 100 18 380 100 
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Table 2 Prevalence of anti-HCV antibodies in subjects hospitalized in surgical or m e d d  departments, or in outpatients 
Surgical 
departments Medical wards Outpatients Total 
No. % No. % No. % No. % 
General population 
Number of subjects 7326 5802 5252 18 380 
HCV Positive 565 7 7 926 16 868 1 6 5  2359 1 2 8  
Males 
Number of subjects 2944 3148 2432 8 524 
HCV Positive 259 8 8  496 1 5 8  473 1 9 4  1228 1 4 4  
Females 
Number of subjects 4382 2654 2820 9 856 
HCV POsihVe 306 7 0  430 162 395 1 4 0  1131 11 5 
Table 3 Serologic profiles observed in HCV RIBA-positive subjects hospitalized in surgical departments or medcal wards, 
and in outpatients 
Surgical 
departments Medical wards Outpatients Total 
No. % No. % No. % No. 96 
Number of subjects 565 926 868 2359 
Three bands RIBA positive 
(C1 oop, c33c, C22p) 358 63.4 646 69.8 641 73.8 1645 69.7 
Two bands RIBA positive 207 36.6 280 30.2 227 26.2 714 30.3 
Table 4 Presence of anti-HCV and anti-HBV (HBcAb) antibodies in 13 598 subjects hospitalized in surgical departments or 
medical wards, and in outpatients 
surgical 
departments Medical wards Outpatients Total 
No. % No. % No. % No. 96 
Number of SUbJeCtS 5473 4022 4103 13598 
HCV Positive 410 7.5 611 1 5 2  652 15.9 1673 12.3 
HBcAb positive 1380 25.2 1226 305 964 23.5 3570 26.3 
of anti-ClOQp, anti-C33c and anti-C22p antibodies, 
whereas 30.3% were positive for only two bands. 
Positivity rates analyzed by department showed 63.4% 
in surgical departments, 69.8% in medical wards and 
73.8% in the outpatient group. 
A comparison between HBV and HCV infections 
was performed on the basis of the antibody prevalence 
and of serologic markers for developing chronic 
infection. 
We compared the prevalences of HBV and HCV 
antibodies in a subgroup of 13 598 sera, taken from the 
main group of 18 380 subjects, on whom both analyses 
had been done. 
Table 4 shows that the prevalence of anti-HCV 
antibodies in this study subgroup was 12.3% versus 
26.3% for anti-HBc antibodies. A lower prevalence of 
anti-HCV antibodies than of anti-core antibodies was 
found in the patients from surgical departments (7.5% 
for HCV versus 25.2% for HBV), in the medical wards 
(15.2% HCV versus 30.5% HBV) and in the out- 
patient group (15.9% HCV versus 23.5% HBV). 
For 15313 subjects, also belonging to the main 
group of 18 380 subjects, both anti-HCV antibodies 
and HBsAg were required. In this group we compared 
the percentage of subjects showing the simultaneous 
presence of anti-C1 OOp, anti-C33c and anti-C22p 
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Table 5 Coniparison between percentages of HCV RIBA-positive and HBsAg-positive subjects in 15 313 subjects 
hospitalized in surgical departments or in medical wards, or in outpatients 
Surgical 
departments Medical wards Outpatients Total 
No. % No. % No. % No. % 
Number of subjects 6449 4587 4277 15313 
HCV RIBA+ 
c100p+, c33c+, C22p’ 290 4.5 413 9.0 473 11.1 1176 7.7 
HBsAG+” 88 1.4 128 2.8 96 2.2 312 2.0 
‘Markers of persistent infection. 
antibodies to the percentage of subjects showing 
persistence of HBsAg in the serum (or the presence of 
both HBsAg and anti-HBc antibodies in the absence of 
anti-HBc IgM and anti-HBs) in order to estimate the 
tendency for each virus infection to become chronic 
(Table 5). 
It was found that 7.7% of the sera were simul- 
taneously positive for antibodies to all three antigens 
(ClOOp, C22p and C33c) of HCV and 2% of the sera 
showed markers of HBV persistent infection. The 
percentage of sera ‘persistently’ positive for HBsAg in 
each group of analyzed subjects was lower than the 
percentage of sera simultaneously positive for anti- 
ClOOp, anti-C22p and anti-C33c antibodies. Moreover, 
17 of 1176 subjects who were anti-CIOOp, anti-C33c 
and anti-C22p positive were also ‘persistently’ positive 
for HBsAg, representing 1.4% of the HCV-positive 
population (data not shown in Table 5 ) .  
DISCUSSION 
We report here the results of a 3-year seroepidemio- 
logic investigation into HCV infection in a large group 
of subjects. The overall prevalence of anti-HCV 
antibodies was evaluated in a population which in- 
cluded subjects hospitalized in surgical departments or 
in medical wards or who were outpatients, and was 
found to be 12.8%. This agrees with the percentage 
positive for HCV infection found in Italy generally 
Previous reports have indicated that HCV infection 
occurs in Italy more frequently in men than in women 
[18]. Our results confirm this at a significant level 
(p<O.Ol). Consequently, the differences observed in 
our surgical departments, as well as in the outpatient 
group, reflect those in the general population. In the 
outpatient group, in particular, the higher percentage 
of positive subjects among males than among females 
could be due to males being investigated on clinical 
~ 7 1 .  
suspicion more often than females, while women were 
often screened before or during pregnancy. 
Grouping the subjects by their different hospital 
departments showed a significant difference in anti- 
HCV antibody prevalence between subjects from 
surgical departments and those from medical wards or 
outpatients. Those in surgical departments were, by 
definition, aged over 20 and were tested as part of 
routine preoperative screening even if they were 
asymptomatic. Thus these subjects can be considered to 
be representative of an asymptomatic general adult 
population with various possible routes of contact with 
HCV. This population differs from blood donors as well 
as from any risk group, which are the target populations 
usually chosen for analysis. In these surgical patients, 
HCV positivity was 7.7% and, among these, 63.4% 
were positive for three bands. 
Three important aspects of HCV progression to 
chronic infection are widely accepted in the literature. 
First, it occurs in 5O-80% of cases [5,19]; second, the 
simultaneous presence of antibodies to ClOOp, C33c 
and C22p HCV antigens correlates closely with the 
presence of virus in the blood [20]; and, third, the 
simultaneous presence of three positive bands can be 
considered to be evidence of a greater risk of develop- 
ing chronic infection [21]. 
These results, from surgical patients, allow us to 
suggest that there is a large number of asymptomatic 
but probably chronically infected subjects in our popu- 
lation. 
The comparison between HBV and HCV in- 
fections, in the population studied, by assessing both 
antibody prevalence and markers for a higher risk of 
chronic infection confirm the finding, by the Italian 
National Surveillance System for Acute Viral Hepatitis 
(SEIEVA), that the prevalence of antibodies to HBV is 
higher than that of antibodies to HCV [17] while, in 
contrast, the frequency of serologic markers indicating 
a trend towards chronicity is higher for HCV than for 
HBV infection. 
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